Cytek Biosciences Inc (CTKB)

Cash ratio

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021
Cash and cash equivalents	US$ in thousands	167,299	163,629	131,500	129,476	296,601	341,523	349,894	362,506	364,618	376,800	159,846
Short-term investments	US$ in thousands	95,111	124,392	167,294	169,519	44,548	—	—	—	—	—	—
Total current liabilities	US$ in thousands	56,226	58,693	53,591	56,517	49,040	41,494	42,350	42,803	33,181	30,014	28,165
Cash ratio		4.67	4.91	5.58	5.29	6.96	8.23	8.26	8.47	10.99	12.55	5.68

December 31, 2023 calculation

Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($167,299K + $95,111K) ÷ $56,226K
= 4.67

The cash ratio measures a company's ability to cover its short-term obligations with cash and cash equivalents. A higher cash ratio indicates a stronger liquidity position as the company has more cash readily available to meet its current liabilities.

Analyzing the cash ratio of Cytek Biosciences Inc over the past several quarters, we observe fluctuations in the ratio. From December 2021 to September 2022, the cash ratio steadily increased from 5.68 to 8.23, indicating a strengthening liquidity position during this period. However, from September 2022 to December 2022, there was a significant jump in the cash ratio from 8.23 to 10.99, suggesting a further improvement in liquidity.

Subsequently, the cash ratio continued to increase, reaching its peak of 12.55 in September 2023, reflecting a substantial amount of cash reserves available to cover short-term obligations. However, in the following quarter, the cash ratio decreased slightly to 4.91 before rising again to 4.67 in December 2023.

Overall, Cytek Biosciences Inc maintained a healthy cash ratio throughout the periods analyzed, signaling solid liquidity management and a strong ability to meet its short-term financial obligations with cash on hand. The fluctuations observed in the cash ratio can be attributed to changes in the company's cash position and short-term liabilities over time.